Tag: Carmustine

Over 47% of childhood brain tumor survivors treated with carmustine and cranial radiotherapy in one long-term study later died from pulmonary fibrosis. Understanding **how toxic is carmustine** is crucial, as this potent alkylating agent is associated with a range of severe and delayed side effects in patients undergoing chemotherapy.

In a retrospective study of 85 newly diagnosed glioblastoma multiforme (GBM) patients, the cohort receiving carmustine wafers had a 2-year survival rate of 47%, compared to 29% for the non-carmustine cohort [1.14.1]. So, **what does carmustine do** to achieve these results? It is a powerful chemotherapy drug used to treat several types of cancer.

As an alkylating agent, carmustine (BCNU) interferes with cancer cell growth by damaging DNA. A primary application of what is carmustine used for is in treating specific types of brain tumors and other serious cancers, both alone and in combination with other therapies.